Early research from the 2026 AAOS Annual Meeting indicates that GLP-1 medications like Ozempic and Wegovy may be associated with a higher relative risk of tendon ruptures. However, with an absolute risk increase of less than 1%, most patients remain unaffected. Discover the proposed mechanisms—from rapid activity increases to collagen signaling—and how to mitigate risk while continuing therapy.